Psychedelics in Palliative Care

End of Life: Psychedelics in Palliative Care

,
We interview Dr. Paul Thielking, Chief Science Officer of Numinus, about the use of psychedelics in palliative care and end of life care
Benzinga Psychedelic Capital Conference Recap with MAPS, Wesana, Felicity Pharma and Irwin Naturals

Interview With Daniel Carcillo, Natalie Ginsberg, Olivia Mannix & Klee Irwin

,
This week on the Psychedelic Spotlight podcast, we provide a recap of the inaugural Benzinga Psychedelic Capital Conference which took place in Fontainebleau Miami Beach on April 19, 2022.

Interview with James Lanthier, CEO of Mindset Pharma

,
CEO of Mindset Pharma, James Lanthier, gives us an overview of his company and the 4 new psychedelics they are creating. He also discusses some big breaking news!

Interview with Matt Stang, CEO of Delic Corp

,
Co-Founder and CEO, Matt Stang, gives us an overview of the company's clinics, Delic Labs and more.

Interview with Patrick Moher, CEO of Microdose

,
In this chat, he discusses some of the challenges involved in moving virtual events to an in-person conference (during a pandemic), who and what to expect at the event, and why Wonderland Miami is not just any other conference, but a one-of-a-kind experience. 

Interview with Bright Minds Biosciences’ CEO Ian McDonald

,
In today’s episode of the Psychedelic Spotlight podcast, the Psychedelic Investor, James Hallifax interviews Ian McDonald, CEO and Director of Bright Minds Biosciences. For any investors out there, you can find Bright Minds Biosciences trading…

Interview with James Lanthier, CEO of Mindset Pharma

,
In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.

Interview with Ian McDonald, CEO & Director of Bright Minds Biosciences

,
In this wide ranging interview many topics are covered, starting with the philosophy and vision of Bright Minds. We discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain. 

Interview with Trevor Millar, Advisor, NeonMind Biosciences

,
In our conversation with Trevor, we have the opportunity to discuss some of the psychedelic-based treatments NeonMind is currently focused on developing to help tackle obesity. Obesity is one of the more prevalent health conditions today affecting millions of individuals worldwide. The World Health Organization has claimed that obesity has reached epidemic proportions globally with at least 2.8 million people dying each year as a result of being overweight or obese.